Biodrugs

Papers
(The TQCC of Biodrugs is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry262
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond173
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making94
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor90
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome79
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis66
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis63
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy56
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design51
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery45
Acknowledgement to Referees44
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials42
CAR-T Cells and the Kidney: Insights from the WHO Safety Database36
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?36
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart34
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies33
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202232
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy31
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic31
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review30
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?30
Malaria Vaccines: Progress to Date29
Progress and Challenges in the Treatment of Fabry Disease29
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data27
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase27
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer26
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?26
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience25
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects25
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series24
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review23
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?23
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options22
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment21
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout20
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network20
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study20
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight19
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine19
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics19
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study18
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis18
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu18
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects17
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy16
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig16
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa16
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 16
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review15
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials15
The Use of Biologics for Thyroid Eye Disease15
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Heal15
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study15
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression14
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database14
Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics14
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab13
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria13
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis13
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases13
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context12
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance12
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease12
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine12
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs12
Patients’ Perceptions of Biosimilars: A Systematic Review12
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies12
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing12
0.047049999237061